DNDN News Alert Dendreon Corp (DNDN) 0.13 12/12/2014 23:55:5

New Post Public Reply Private Reply Replies (0) Message Board

Dec 13, 2014 at 12:55 AM

Dendreon Corp (DNDN) 0.13 $DNDN

Using Re-Engineered Immune Cells to Kill Leukemia Induces Lasting Remissions
at The Street - Sat Dec 06, 12:00PM CST
A new form of cancer immunotherapy known as CAR-T promises to radically change the way certain blood cancers are treated.
BLUE: 91.28 (+5.16), KITE: 54.79 (+0.39), DNDN: 0.13 (-0.02), NVS: 93.52 (-0.82), CELG: 114.49 (-2.25)

A New Combined Approach to Cancer Immunotherapy is Needed
ACCESSWIRE - Mon Dec 01, 11:35AM CST
NEW YORK, NY / ACCESSWIRE / December 1, 2014 / With the recent bankruptcy of Dendreon Corporation (NASDAQ

NDN) due to disappointing sales of its flagship Provenge prostate cancer vaccine, the future of cancer immunotherapy just got a bit cloudier. While Provenge itself will survive, Dendreon may end up going private in a debt restructuring deal.
DNDN: 0.13 (-0.02), AMGN: 164.53 (-1.55), LLY: 69.55 (-2.06), BMY: 58.75 (-0.93)

Northwest Biotherapeutics' DCVax-L: A Reimbursement Perspective
Ryan Pawell - at Seeking Alpha - Sun Nov 23, 3:41AM CST

NWBO: 4.98 (+0.04), DNDN: 0.13 (-0.02)

Most active Nasdaq-traded stocks
AP - Tue Nov 18, 5:03PM CST
NEW YORK (AP) — A look at Nasdaq 10 most-active stocks at the close of trading:
SPLS: 16.47 (+0.37), GILD: 104.13 (-0.18), FB: 77.83 (+0.10), DNDN: 0.13 (-0.02), MSFT: 46.95 (-0.22), INTC: 36.22 (-0.48), GRPN: 7.22 (-0.04), AAPL: 109.73 (-1.89), CSCO: 26.85 (-0.14)

Will Patterson Companies (PDCO) Surprise Earnings in Q2? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 18, 4:40PM CST
Patterson Companies (PDCO) had a mixed first quarter in which revenues beat the Zacks Consensus Estimate while adjusted earnings fell shy.
KR: 61.55 (-0.34), DNDN: 0.13 (-0.02), BBY: 36.85 (+0.22), PDCO: 47.44 (-0.72)

Market Maker Surveillance Report. DNDN, YHOO, CRDC, FNMAS, SLTD, BABA, Highest Net Sell Volume and Negative Price Friction For Thursday, November 13th 2014
M2 - Fri Nov 14, 3:02AM CST
BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Thursday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Thursday there were 4759 companies with "abnormal" market making, 1814 companies with positive Friction Factors and 3114 companies with negative Friction Factors. Here is a list of the top companies with the highest net sell volume on Thursday and lowest negative price Friction (bearish). This means that there was more selling than buying in the stocks and their stock prices dropped faster with less Friction. Dendreon Corp (NASDAQ

NDN), Yahoo! Inc (NASDAQ:YHOO), Cardica Inc (NASDAQ:CRDC), Federal National Mortgage Association Fannie Mae (OTC:FNMAS), Solar3D Inc (OTC:SLTD), (NYSE:BABA). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks please visit http://www.buyins.net .
YHOO: 50.24 (+0.30), DNDN: 0.13 (-0.02), CRDC: 0.62 (-0.02), BABA: 105.11 (+0.14)

Political Intelligence Rules Urged On D.C. Insiders
at Investor's Business Daily - Thu Nov 13, 5:54PM CST
The term "political intelligence" may sound like an oxymoron, but it can make a difference in investors' portfolios and has drawn the eye of legislators and investigators. Political intelligence is the business of people providing information about...
DNDN: 0.13 (-0.02), UNH: 98.76 (-0.97), AET: 87.30 (-0.82), HUM: 143.60 (+1.12)

Biotech Stock Roundup: Gilead, AbbVie Score at Liver Meeting, Dendreon Files for Bankruptcy - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Nov 12, 7:48AM CST
Companies like AbbVie (ABBV), Gilead (GILD) and Achillion (ACHN) had a strong presence at the annual Liver Meeting.
VRTX: 118.55 (-2.23), GILD: 104.13 (-0.18), ACHN: 13.28 (-0.11), DNDN: 0.13 (-0.02), AMGN: 164.53 (-1.55), ABBV: 65.27 (-1.76), REGN: 416.44 (-7.91)

Earnings Forecast Recap for Alibaba, Apple, Zynga, Gilead Sciences, Dendreon, and Juniper
PR Newswire - Wed Nov 12, 7:45AM CST
EarningForecast.com has issued six earnings forecast research reports with special focus on financial performance of the following stocks: Alibaba (NYSE:BABA), Apple (NASDAQ:AAPL), Zynga (NASDAQ:ZNGA), Gilead Sciences (NASDAQ:GILD), Dendreon (NASDAQ

NDN), and Juniper (NYSE:JNPR).
GILD: 104.13 (-0.18), DNDN: 0.13 (-0.02), ZNGA: 2.50 (+0.03), AAPL: 109.73 (-1.89), JNPR: 21.10 (-0.27), BABA: 105.11 (+0.14)

Nasdaq stocks posting largest volume increases
AP - Tue Nov 11, 5:02PM CST
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
HEAR: 3.82 (+0.22), LSBK: 13.36 (-0.11), VSAR: 18.69 (+0.24), SANW: 3.75 (-0.20), URRE: 1.98 (+0.09), EDUC: 4.75 (+0.03), MCEP: 6.50 (-0.07), CYAN: 5.90 (-0.16), DNDN: 0.13 (-0.02), SUMR: 2.78 (+0.10), CRTN: 4.19 (+0.16)

Dendreon Shares Plummet After It Files for Bankruptcy - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 11, 3:45PM CST
Dendreon filed voluntary petitions under Chapter 11 of the Bankruptcy Code in the U.S. Bankruptcy Court for the District of Delaware.
MDVN: 106.86 (-1.16), AGN: 208.47 (-2.67), JNJ: 104.43 (-2.29), DNDN: 0.13 (-0.02)

Update: Dendreon Bankruptcy
Alexander Maxwell - at Seeking Alpha - Tue Nov 11, 12:55PM CST

DNDN: 0.13 (-0.02)

Clarification: Dendreon-Chapter 11 Filing story
By The Associated Press - AP - Tue Nov 11, 12:43PM CST
In a story Nov. 10, The Associated Press reported that Bank of New York Mellon was listed as the largest creditor in a Chapter 11 bankruptcy court filing involving the drugmaker Dendreon Corp. BNY Mellon administers $620 million in notes for investors; it does not own them.
DNDN: 0.13 (-0.02)

Bankruptcies, Breakouts, and Busts; What's Happening in Biotech?
ACCESSWIRE - Tue Nov 11, 10:34AM CST
CORAL GABLES, FL / ACCESSWIRE / November 11, 2014 / From prostate cancer drugs to stem-cell therapy, the biotech industry seems to encompass a variety of unique and innovative companies. According to market research firm IBISWorld, the global revenue of the Biotech industry is nearly $300 billion. Statista reports that more that $50Billion of US biopharmaceutical goods are exported and the industry is on pace to grow at a compounded annual rate of nearly 11%. IBIS notes that many small companies, alongside a few industry giants in pharmaceutical, chemical and agricultural firms, populate the global biotech industry. There is also a lower level of market share concentration as noted by IBISWorld estimates that the top four industry players will account for less than 28% of the industry's revenue in 2014. With so much potential there are certainly companies in the market, which have progressed to the next level and others that have mismanaged their businesses into bankruptcy.
DNDN: 0.13 (-0.02)

Are Expensive Biotech Drugs Bad For Business?
Keith Williams - at Seeking Alpha - Tue Nov 11, 9:45AM CST

VRTX: 118.55 (-2.23), GILD: 104.13 (-0.18), MRK: 57.72 (-1.62), DNDN: 0.13 (-0.02), AZN: 71.80 (-1.80), TEVA: 55.92 (-0.92), ABBV: 65.27 (-1.76), GSK: 42.42 (-0.93), BMY: 58.75 (-0.93), NVS: 93.52 (-0.82)

Stock Market Today: S&P 500 Eyes Strong Finish for 2014; Alibaba Spikes
at The Street - Mon Nov 10, 2:02PM CST
Though the S&P 500 has rallied to record highs over the past three weeks, analysts predict markets will continue to climb through to year's end.
KSS: 57.27 (+0.37), GPRO: 60.52 (+0.47), DNDN: 0.13 (-0.02), MCD: 90.62 (-0.35), M: 62.36 (+1.14), TWC: 145.12 (-2.03), TOL: 31.56 (-0.57), CMCSA: 55.35 (-0.55), BABA: 105.11 (+0.14)

Will Puma Biotechnology (PBYI) Disappoint this Earnings? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 10, 1:40PM CST
Puma Biotechnology (PBYI) is expected to report third-quarter 2014 results before the opening bell on Nov 11.
MNK: 94.72 (-0.36), DNDN: 0.13 (-0.02), PFE: 30.95 (-0.70), PBYI: 196.34 (-7.66)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Innovative Trial Targets Drug Resistance in Lung Cancer

The Battle Against Drug Resistance Heats Up Folks, we're in a never-ending fight here against one of the toughest adversaries out there: lung cancer. And lemme tell ya, when drugs show resistance, it's like trying to punch a ghost. But there’s a fresh wind blowing, as Dr. Bobak Parang steps up to the plate with a $620K grant aimed squarely at tackling drug resistance in...

Right College Fit Crucial for Graduation Rates

Navigating College Choices: More Than Just a Hunch When it comes to picking the right college, a lot of folks think it's like shooting in the dark—it's more than just a blind dart throw at a life map. According to a new report from the College Board, aligning with the right academic institution isn't merely a nice-to-have deal; it fundamentally shifts the odds in favor...

Abbe Lane's Estate Auction: Glamour Up for Grabs

Glamour from the Mid-Century Comes to the Auction Block In a world obsessed with the flavor of the month, a collection that truly turns heads by sailing in on a wave of genuine mid-century splendor isn't something you stumble upon every day. John Moran Auctioneers has the privilege to crack open the vault on the Estate of Abbe Lane, a name that once rolled off tongues...

J.H. Strain & Sons' Asset Sale Seals a New Era

Texan Legacy Bows Out of the Asphalt Game Here's a fresh chapter in the world of road construction that'll have folks in the industry doing a double-take. Elder Bray & Bankler, a bigwig among corporate law circles, has been guiding this tale. They've shepherded J.H. Strain & Sons through selling off its asphalt manufacturing and construction assets to none other than...

Navigate360 Data Breach Concerns: Legal Insights

No Safety in a Storm: Navigate360's Data Breach Fiasco When you think of data breaches, you often envision some shady hacker in a hoodie, but here we are with Navigate360 losing control of a massive chunk of sensitive data involving school safety tips. You'd hope companies with serious access to personal information are better at keeping secrets, right? Yet, here we are,...

Sinopec's Bold African Moves: Sustainability and WE17

A Bold African Initiative Alright, folks, let's get into the nitty-gritty of Sinopec's game plan in Africa. There's something to be said about a behemoth like Sinopec rolling out a sustainability report with real substance. We're looking at 33 projects across 16 countries, $5.7 billion in investments. Now, that's not just pocket change. Economic Muscle and Environmental...

A&S Construction Creates Winning Culture in Louisville

A&S Construction's Winning Formula: Culture Over Growth Look, in the dog-eat-dog world of construction, what really sets you apart isn't just how many roofs you stack up or the number of renovations you churn through. It's how you treat your people. And A&S Construction of Louisville gets that—ranking No. 6 in its category on the 2026 Best Places to Work list, all while...

SELCO and Numerica Unite: A Merger That's All Heart

Big Merger in Credit Union World: SELCO and Numerica Sometimes, it ain't all about dollars and cents. That's the vibe I'm picking up from this merger of equals between SELCO Community and Numerica Credit Unions. This isn't a Wall Street hustle, it's hometown hustle—where the biggest reward isn't just a fat line at the bottom but seeing your community thrive. The Vision...

Ameritas Hires Actuarial Veteran as VP in Strategic Move

Shifting Gears at Ameritas: New VP Takes the Helm Well, chalk one up for Ameritas on this move. They've just brought on Ying Zhao as the new vice president of actuarial and financial strategy. It's a mouthful of a title, sure, but it's the role itself that's worth watching. Ameritas, for those not tracking, is a major player in the insurance and financial universe, doing...

Fed Holds Steady, But CD Rates Climb: Savers' Edge

The Fed Sits Tight, But CD Rates Surge Isn't it a kicker when the Fed holds rates steady, yet the CD market is buzzing like a crowded trading floor on a bull run? We've seen the Federal Reserve hold its ground without budging interest rates, keeping everyone guessing while inflation's still a shadow in the corner. But the star of the show here isn't the Fed's poker...